Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant ...

Among stable, relatively low-risk patients who had previously suffered a heart attack, discontinuing beta-blockers after at ...

HRS-1893 (also known as BHB-1893) is a selective, small-molecule, cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By modulating cardiac contractility, HRS-1893 ...

In stabilized heart attack survivors without heart failure or left ventricular (LV) systolic dysfunction, stopping the ...

The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.

Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported late breaking echocardiography results from its Phase ...

BioCardia ( (BCDA)) has issued an announcement. On March 3, 2026, BioCardia reported late-breaking echocardiography data from its Phase III CardiAMP HF trial in ischemic heart failure with reduced ...

Treatment management guided by the use of a noninvasive device to monitor fluid accumulation in the lungs substantially reduced hospitalizations and deaths among patients with heart failure with ...

The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary ...

Earlier this week, Merck & Co., Inc. reported detailed Phase 2 CADENCE results showing WINREVAIR (sotatercept-csrk) significantly reduced pulmonary vascular resistance in adults with combined post- ...

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and ...